JASPER THERAPEUTICS, INC. Increase (Decrease) in Other Current Liabilities
JASPER THERAPEUTICS, INC. (JSPR) reported Increase (Decrease) in Other Current Liabilities of -$32.00 thousand for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-11.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentLiabilities · last filed 2023-08-11
- JASPER THERAPEUTICS, INC. increase (decrease) in other current liabilities for the quarter ending 2023-06-30 was -$16.00K, a 114.55% decline year-over-year.
- JASPER THERAPEUTICS, INC. increase (decrease) in other current liabilities for the quarter ending 2023-03-31 was -$16.00K, a 1700.00% decline year-over-year.
- JASPER THERAPEUTICS, INC. increase (decrease) in other current liabilities for the quarter ending 2022-12-31 was $1.65M.
- JASPER THERAPEUTICS, INC. increase (decrease) in other current liabilities for the quarter ending 2022-09-30 was -$40.00K, a 139.22% decline year-over-year.
- JASPER THERAPEUTICS, INC. increase (decrease) in other current liabilities for fiscal 2022 was $1.72M.
- JASPER THERAPEUTICS, INC. increase (decrease) in other current liabilities for fiscal 2021 was -$200.00K, a 200.00% decline from fiscal 2020.
- JASPER THERAPEUTICS, INC. increase (decrease) in other current liabilities for fiscal 2020 was $200.00K.
| Period end | Increase (Decrease) in Other Current Liabilities 3 month | Increase (Decrease) in Other Current Liabilities 6 month | Increase (Decrease) in Other Current Liabilities 9 month | Increase (Decrease) in Other Current Liabilities 12 month |
|---|---|---|---|---|
| 2023-06-30 | -$16.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$32.00K 10-Q · filed 2023-08-11 | $1.62M derived: sum of 3 quarters · filed 2023-08-11 | $1.58M derived: sum of 4 quarters · filed 2023-08-11 |
| 2023-03-31 | -$16.00K 10-Q · filed 2023-05-12 | $1.63M derived: sum of 2 quarters · filed 2023-05-12 | $1.59M derived: sum of 3 quarters · filed 2023-05-12 | $1.70M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-12-31 | $1.65M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $1.61M derived: sum of 2 quarters · filed 2023-03-08 | $1.72M derived: sum of 3 quarters · filed 2023-08-11 | $1.72M 10-K · filed 2023-03-08 |
| 2022-09-30 | -$40.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $70.00K derived: sum of 2 quarters · filed 2023-08-11 | $71.00K 10-Q · filed 2022-11-10 | -$31.00K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-06-30 | $110.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $111.00K 10-Q · filed 2023-08-11 | $9.00K derived: sum of 3 quarters · filed 2023-08-11 | $111.00K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $1.00K 10-Q · filed 2023-05-12 | -$101.00K derived: sum of 2 quarters · filed 2023-05-12 | $1.00K derived: sum of 3 quarters · filed 2023-05-12 | -$200.00K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | -$102.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $0.00 derived: sum of 2 quarters · filed 2023-03-08 | -$201.00K derived: sum of 3 quarters · filed 2023-03-08 | -$200.00K 10-K · filed 2023-03-08 |
| 2021-09-30 | $102.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$99.00K derived: sum of 2 quarters · filed 2022-11-10 | -$98.00K 10-Q · filed 2022-11-10 | -$300.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$201.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$200.00K 10-Q · filed 2022-08-12 | -$402.00K derived: sum of 3 quarters · filed 2022-08-12 | |
| 2021-03-31 | $1.00K 10-Q · filed 2022-05-12 | -$201.00K derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$202.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $200.00K 10-K · filed 2022-03-18 | ||
| 2020-09-30 | $402.00K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |